Therapeutic Antibodies & Biosimilar ELISA Kits
Sensitive, quantitative free-drug and anti-drug antibody (ADA) ELISA kits for pharmacokinetic, immunogenicity and biosimilarity studies — covering 30+ biologics including adalimumab, trastuzumab, pembrolizumab, nivolumab, rituximab and tocilizumab.
Screening and quantification of biologic drugs in serum and plasma.
For QC, PK and biosimilarity assessment against the reference product.
Detect anti-drug antibodies — qualitative, quantitative and free/total.
Bespoke assay development for your drug on request. Contact us.
Quality control during development and manufacture, biosimilarity assessment against the reference product, pharmacokinetic (PK) studies to guide dosing, and monitoring of drug levels in samples during clinical development.
Immunogenicity assessment, analysis of response variability between subjects, biosimilar immunogenicity profiling, and free-vs-total ADA measurement using acid dissociation to break drug–ADA complexes.
Pre-coated capture reagent binds the drug or ADA from serum or plasma.
An enzyme-linked detection antibody binds the captured analyte.
Substrate produces a colour change proportional to analyte level.
Measure OD on a plate reader and read off the standard curve.
Detection in the ng/mL range in serum and plasma.
Under 25 µL of sample per test.
Complete in 70–140 minutes.
85–115% recovery, validated in human samples.
Lot-to-lot consistency for longitudinal studies.
Qualitative, quantitative and free/total kits.
Free-drug kits quantify a biologic in serum or plasma for QC, biosimilarity and PK studies; ADA kits detect anti-drug antibodies for immunogenicity assessment. All kits are for research use only.
Yes — qualitative, quantitative and free/total ADA formats are available. Free/total ADA kits use acid dissociation to break drug–ADA complexes so both free and complexed ADA can be measured.
Detection is in the ng/mL range with recovery of 85–115%, typically using under 25 µL of sample and completing in 70–140 minutes.
More than 30 therapeutic antibodies and biosimilars across anti-TNF, oncology, checkpoint inhibitor, anti-inflammatory, wet AMD and allergy drugs — including adalimumab, infliximab, trastuzumab, bevacizumab, rituximab, pembrolizumab, nivolumab and tocilizumab. Browse the full range in the product listing below.
Yes. If your biologic isn't listed, our PhD-level team can develop a custom free-drug or ADA ELISA — get in touch.